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Abstract
Background: Cervical cancer is a major public health problem in Malawi. The age-standardized incidence and
mortality rates are estimated to be 75.9 and 49.8 per 100,000 population, respectively. The availability of the human
papillomavirus (HPV) vaccine presents an opportunity to reduce the morbidity and mortality associated with
cervical cancer. In 2013, the country introduced a school-class-based HPV vaccination pilot project in two districts.
The aim of this study was to evaluate HPV vaccine coverage, lessons learnt and challenges identified during the first
three years of implementation.
Methods: This was an evaluation of the HPV vaccination project targeting adolescent girls aged 9–13 years
conducted in Malawi from 2013 to 2016. We analysed programme data, supportive supervision reports and minutes
of National HPV Task Force meetings to determine HPV vaccine coverage, reasons for partial or no vaccination and
challenges. Administrative coverage was validated using a community-based coverage survey.
Results: A total of 26,766 in-school adolescent girls were fully vaccinated in the two pilot districts during the first
three years of the programme. Of these; 2051 (7.7%) were under the age of 9 years, 884 (3.3%) were over the age
of 13 years, and 23,831 (89.0%) were aged 9–13 years (the recommended age group). Of the 765 out-of-school
adolescent girls aged 9–13 who were identified during the period, only 403 (52.7%) were fully vaccinated. In
Zomba district, the coverage rates of fully vaccinated were 84.7%, 87.6% and 83.3% in year 1, year 2 and year 3 of
the project, respectively. The overall coverage for the first three years was 82.7%, and the dropout rate was 7.7%. In
Rumphi district, the rates of fully vaccinated coverage were 90.2% and 96.2% in year 1 and year 2, respectively,
while the overall coverage was 91.3%, and the dropout rate was 4.9%. Administrative (facility-based) coverage for
the first year was validated using a community-based cluster coverage survey. The majority of the coverage results
were statistically similar, except for in Rumphi district, where community-based 3-dose coverage was higher than
the corresponding administrative-coverage (94.2% vs 90.2%, p < 0.05), and overall (in both districts), facility-based
1-dose coverage was higher than the corresponding community-based (94.6% vs 92.6%, p < 0.05). Transferring out
of the district, dropping out of school and refusal were some of the reasons for partial or no uptake of the vaccine.
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Conclusion: In Malawi, the implementation of a school-class-based HPV vaccination strategy was feasible and
produced high (>80%) coverage. However, this strategy may be associated with the vaccination of under- and
over-aged adolescent girls who are outside of the vaccine manufacturer’s stipulated age group (9–13 years). The
health facility-based coverage for out-of-school adolescent girls produced low coverage, with only half of the target
population being fully vaccinated. These findings highlight the need to assess the immunogenicity associated with
the administration of a two-dose schedule to adolescent girls younger or older than 9–13 years and effectiveness
of health facility-based strategy before rolling out the programme.
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Background
Globally, cervical cancer has been identified as the fourth
most common cancer in women (after breast, colorectum
and lung), with an estimated 528,000 new cases and
266,000 deaths occurring each year. The majority (>85%)
of global cervical cancer morbidity and mortality occur in
developing countries and the highest risk is in eastern and
southern Africa [1, 2]. Virtually all cervical cancer cases
(99%) are caused by human papilloma virus (HPV), with
HPV types 16 and 18 causing 70% of the cases and pre-
cancerous lesions. HPV is transmitted through sexual con-
tact and is the most common viral infection of the
reproductive tract [3, 4]. Currently, there are two WHO
prequalified vaccines that protect against both HPV type
16 and 18. One of the vaccines also protects against HPV
types 6 and 11, which cause anogenital warts. HPV vac-
cines are administered before the onset of sexual activity,
i.e., before exposure to HPV infection. For quadrivalent
HPV vaccine, WHO recommends a 2-dose schedule
(0.5 ml at 0 and 6 months) for adolescents aged 9–13 years
and a 3-dose schedule (0.5 ml at 0, 1, 6 months) for those
aged 14 years or more. For bivalent vaccine, 2-dose sched-
ule is recommended for the age group of 9–14 years and a
3-dose schedule for those aged 15 years or more [5].
In Malawi, cervical cancer is a major public health prob-
lem. The age-standardized incidence and mortality rates
(ASRs) are estimated to be 75.9 and 49.8 per 100,000 popu-
lation, respectively. It is the commonest cancer in women
accounting for 45.4% of all cancers and the trend is increas-
ing. It is estimated that every year, 3684 women develop
cervical cancer, and 2314 women die from the disease
[6–9]. The median and 5-year survival rates from the time
of diagnosis have been reported to be 10 months and 2.9%,
respectively [10]. The high prevalence of HPV (33.6%), co-
infection with HIV (10.8%) and inadequate screening and
treatment services for precancerous lesions have been iden-
tified as the main risk factors for high cervical cancer inci-
dence and mortality. Overall, Malawi has a population of
4.76 million women aged 15 years and older who are at risk
of developing cervical cancer [8, 9, 11, 12].
Ministry of Health through its Reproductive Health
(RH) Directorate has been implementing a national
cervical cancer screen-and-treat programme using visual
inspection with acetic acid (VIA) and cryotherapy since
2004 [13]. In 2013, with support from the Global Alliance
for Vaccines and Immunization (GAVI), the country intro-
duced HPV vaccination demonstration project. This study
aimed to evaluate HPV vaccine coverage, lessons learnt
and challenges identified during the first three years of
implementation.
Methods
HPV vaccination delivery strategy
For in-school adolescent girls, school-class-based strat-
egy was implemented. For out-of- school, a health
facility-based strategy was used. According to data from
the education management information system (EMIH),
majority (>85%) of girls aged 9–13 years are in standard/
grade 4. Standard 4 was therefore selected, and all the
girls in that class irrespective of age were eligible to re-
ceive the vaccine. Out-of-school girls aged 9–13 years
were identified and registered in the communities by
community health workers with support from the com-
munity chiefs. The parents or caregivers of out-of-school
girls were advised to take them to the nearest health fa-
cility during the vaccination week.
Vaccine type and administration
Malawi successfully applied to GAVI and sourced Gardasil®
(Merck & Co., USA); a quadrivalent HPV vaccine that pre-
vents infections from the four HPV genotypes (6, 11 and
16, 18) that are the most common cause of cervical cancer
(HPV types 16 and 18) and genital warts (HPV types 6 and
11) [3–5]. The vaccines were administered by health sur-
veillance assistants (HSAs), who are government-employed
community health workers who administer routine ex-
panded programme of immunization (EPI) vaccines and
other preventive and disease surveillance interventions. At
the school, there was an HPV registry for all girls in stand-
ard 4 and their HPV vaccination status. Each girl was given
an HPV vaccination card on which doses and date given
were recorded.
The intervention was planned and supervised by
three sections of the Ministry of Health – the Non-
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communicable Diseases (NCDs) Unit, the EPI Unit and
the RH Department – in collaboration with the Ministry
of Education School Health and Nutrition Department
and School Inspection Unit. Technical support was pro-
vided by WHO, UNICEF, CHAI and PATH.
Demonstration districts
Rumphi district, located in northern region, was selected
to represent a rural district, while the Zomba district, lo-
cated in the southern region, was chosen to represent
both urban and rural settings.
Study type
This was a cross-sectional study with two arms: facility-
and community-based with the aim of documenting ad-
ministrative- and community- based vaccine coverage,
respectively. The facility-based arm was evaluated by
compiling and analysing data from schools and health
facilities in the two implementing districts and reviewing
supportive supervision reports and minutes of National
Task Force meetings.
To validate administrative vaccine coverage and iden-
tify reasons for partial or no vaccination, a community-
based vaccine coverage survey was conducted. WHO
immunization cluster survey guidelines (popularly
known as the 30 by 10 method) were used to randomly
select 30 clusters (enumeration areas (EA)) from each of
the two districts using the probability proportional to
size (PPS) sampling method. In each cluster, 10 eligible
households with a girl in standard 4 or out- of- school
aged 9–13 years were selected using a systematic sam-
pling method. Data were collected using a standardized
structured questionnaire. The questionnaire was designed
to collect information on the demographic characteristics
of the eligible girl and her caregiver; status of HPV
immunization, including the dates and location where the
vaccine was received; reasons for vaccine acceptance or
non-acceptance; exposure to information from education
and communication (IEC) materials and messages; and
knowledge and perceptions of the HPV vaccine. Verbal re-
ports from parents or caregivers regarding the vaccination
status of the girls were verified using vaccination cards,
where available, or the school’s HPV registry.
Data management
Data were entered into a Microsoft Excel® spreadsheet
and exported to Epi Info version 7 (Centers for Disease
Control, Atlanta, GA, USA) and SPSS for Windows ver-
sion 20 (Chicago, IL, USA) for analysis. Chi-square tests
were used to evaluate differences between administrative
and community- based coverage and drop- out rates be-
tween the 1st and 2nd dose. All analyses were performed
using 95% confidence levels, and p < 0.05 was consid-
ered statistically significant.
Results
Characteristics of adolescent girls enrolled in the HPV
vaccination demonstration project 2013–2016
A total of 26,766 in-school adolescent girls were fully
vaccinated in the two pilot districts during the first three
years of the project. Of these; 2051 (7.7%) were under
the age of 9 years, 884 (3.3%) were over the age of
13 years, and 23,831 (89.0%) were aged 9–13 years (the
recommended age group). Of the 765 out-of-school ado-
lescent girls aged 9–13, only 403 (52.7%) were fully vac-
cinated (Table 1).
HPV vaccination coverage
In Zomba district, the coverage rates of fully vaccinated
were 84.7%, 87.6% and 83.3% in year 1, year 2 and year 3
of the project, respectively. The overall coverage for the
first three years was 82.7%, and the dropout rate was
7.7%. In Rumphi district, the coverage rates of fully vac-
cinated were 90.2% and 96.2% in year 1 and year 2, re-
spectively, and the overall coverage and dropout rates
were 91.3% and 4.9%, respectively. In Rumphi, 2nd dose
was not administered during year 3 (Table 2). The admin-
istrative (facility-based) coverage for the first year was vali-
dated based on community-based coverage. The majority
of the 3-dose coverage rates were statistically similar, ex-
cept for in the Rumphi district, where community-based
coverage was higher than administrative-coverage (94.2%
vs 90.2%, p < 0.05), and overall (both district), facility-
based 1-dose coverage was higher than community-based
coverage (94.6% vs 92.6%, p < 0.05). The reasons for these
differences were unknown (Table 3).
Reasons for no or partial vaccination
The analysis of 65 in-school adolescent girls in Zomba
who did not receive all the doses revealed that no or
partial vaccination coverage occurred because of the fol-
lowing as reasons: 50 (76.9%) girls were transferred out
of the district, 7 (10.8%) girls dropped out of school, 6
(9.2%) girls refused (of whom 5 were self-refusal and 1
was a parental refusal) and 2 (3.1%) girls were absent
during the time when the 2nd dose was administered.
Community-based data from 81 parents/caregivers of
the adolescent girls who did not complete the three doses
in year one of the project revealed that refusal to be vacci-
nated by the girl, inconvenient location/time, and parent/
caregiver beliefs that the vaccine was not good for the girls
and that the vaccination site was unclean and/or unsafe
were the most common reasons for partial or no uptake
of the vaccine, accounting for 26.2%, 19.1%, 11.9% and
9.5% of refusals, respectively (Table 4).
Discussion
This study showed that it was feasible and acceptable to
administer HPV vaccine to adolescent girls using school-
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class-based strategy in Malawi. High coverage of fully
immunized (at least 2 doses) of 86.5%, 91.1% and 83.3%
were achieved in year 1, 2 and 3, respectively.
Cumulatively, at least 26,766 in-school adolescent girls
were fully vaccinated during the first 3 years of the
project High immunization coverage rates using school-
class-based strategy was also reported in Tanzania
(83.8%), Uganda (87.8%) and Rwanda (93.2%). Strong co-
ordination between health and education officials,
designing delivery strategy based on a good understand-
ing of the current system and opportunities for synergy,
active involvement of teachers, implementation through
the regular EPI system structure, human resources,
and government endorsement and ownership of the
programme have been reported to be factors that facilitate
the achievement of high rates of HPV vaccine coverage
using school-based programmes [14–16]. In addition,
compared with health facility-based strategies, the use of
Table 1 Age of standard/grade four girls who received HPV vaccine
Year 1 (2013–2014) Year 2 (2014–2015) Year 3 (2015–2016) Total for the first 3 years
of the project
Zomba
urban (%)
Rumphi
District (%)
Total
(%)
Zomba
urban (%)
Rumphi
District (%)
Total
(%)
Zomba
district (%)
Rumphi
District (%)
Total
(%)
Zomba
district (%)
Rumphi
District (%)
Total
(%)
Total in-school
standard 4 girls
fully vaccinated:
1635 3874 5509 1506 3055 4561 13,532 3164 16,696 16,673 10,093 26,766
≤8 years old 377 (23.1) 267 (6.9) 644
(11.7)
294 (19.5) 223 (7.3) 517
(11.3)
695 (5.1) 195 (6.2) 890
(5.2)
1366 (8.2) 685 (6.8) 2051
(7.7)
9–13 years old 1241
(75.9)
3484
(89.9)
4725
(85.8)
1176
(78.1)
2760
(90.3)
3936
(86.3)
12,252
(90.5)
2918
(92.2)
15,170
(91.0)
14,669
(88.0)
9162
(90.8)
23,831
(89.0)
≥14 17 (1.0) 123 (3.2) 140
(2.5)
36 (2.4) 72 (2.4) 108
(2.4)
585 (4.3) 51 (1.6) 636
(3.8)
638 (3.8) 246 (2.3) 884
(3.3)
Out-of-school
girls aged 9–13
years vaccinated
- - - 4/4
(100.0)
28/58
(48.3)
32/62
(51.6)
368/701
(52.5)
3/3 (100.0) 371/
704
(52.7)
372/705
(52.8)
31/60
(51.7)
403/
765
(52.7)
Total number
of girls fully
vaccinated
1635 3874 5509 1510 3083 4593 13,900 3167 17,067 17,045 10,124 27,169
In year one, fully vaccinated was defined receiving all the three (3) doses given at 0,2 and 6 months. In year 2 and 3, fully vaccinated was defined receiving two
doses given at 0 and 6 months
Table 2 School-class-based HPV coverage for the first three years of the project
Year 1 (2013–2014) Year 2 (2014–2015) Year 3 (2015–2016) Overall; the first 2 or 3 years of the project
1 Dose 2 Doses 3 Doses 1 Dose 2 Doses 1 Dose 2 Doses 1 Dose Fully vaccinated
Zomba:
Target 1930 1930 1930 1720 1720 16,531 16,531 20,181 20,181
No. vaccinated 1760 1675 1635 1575 1506 14,911 13,532 18,246 16,673
Coverage 91.2% 86.8% 84.7% 91.6% 87.6% 90.2% 83.3% 90.4% 82.7%
Dropout rate ref 4.4% 6.5% ref 4.0% ref 6.9% ref 7.7%
Rumphi:
Target 4294 4294 4294 3296 3296 3303 3303 7590 7590a
No. vaccinated 4130 4002 3874 3169 3055 3167 - 7299 6929
Coverage 96.2% 93.2% 90.2% 96.2% 92.7% 95.9% - 96.2% 91.3%
Dropout rate ref 3.0% 6.0% ref 3.5% ref - ref 4.9%
Both districts:
Target 6224 6224 6224 5016 5016 19,834 19,834 11,240 11,240a
No. vaccinated 5890 5677 5509 4744 4561 18,078 - 10,634 10,070
Coverage 94.6% 91.2% 88.5% 94.6% 90.9% 91.2% - 94.6% 89.6%
Dropout rate ref 3.4% 6.1% ref 3.7% ref ref 5.0%
Ref reference, aIn Rumphi results for fully vaccinated were for the first two years
In year one, fully vaccinated was defined receiving all the three (3) doses given at 0, 2 and 6 months. In year 2 and 3, fully vaccinated was defined receiving two
doses given at 0 and 6 months
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school-based strategies has been found to reduce oper-
ational problems for parents or caregivers [17].
The other lesson learnt from this study was that the
school-class-based strategy is likely to include girls out-
side the vaccine manufacturers’ stipulated age group of
9–13 years. Of the 26,766 girls that were fully
vaccinated; 2051 (7.7%) and 884 (3.3%) were aged less
than 9 and more than 13 years, respectively. Up to 21%
of standard 4 girls in urban schools were aged less than
9 years, whereas those aged 14 years and older were
mainly identified in rural areas. Safety and efficacy data
regarding the vaccination of girls aged 8 years or less are
not readily available. Nevertheless, no serious adverse
event following immunization was reported in general
and in girls aged 8 years or less or 14 or more in par-
ticular. For girls aged 14 years or older, the vaccine
manufacturer stipulates that a 3-dose (0.5 mL at 0, 2,
6 months) schedule should be administered for quadri-
valent HPV vaccine. However, when using a class-based
strategy, it might not be feasible to administer 3 doses to
some girls while the rest receive 2 doses. Therefore,
when the decision was made to change from a 3- to 2-
dose schedule, all the girls in standard/grade 4 received
a 2-dose schedule regardless of age. It was not known
whether immunogenicity of those aged 8 years and less
or 14 years and older were similar or inferior to those
aged 9–13 years.
Most countries in southern Africa implemented
school-based vaccination strategy during the HPV dem-
onstration project. Therefore, data collected based on
health facility-based strategy is scarce. Our demonstra-
tion project included a sizeable number of out-of-school
girls, particularly when the project was scaled-up to the
whole district of Zomba, who were vaccinated using a
health facility-based strategy and, therefore, provided
some insight on the coverage associated with the applica-
tion of this strategy. Of the 765 of-out-school girls who
were identified and parents/caregivers were advised to
take them to the nearest health facility for vaccination,
only half (53%) were fully vaccinated. This result occurred
despite intensified community mobilization campaign.
Table 3 Validation of Year 1 HPV Vaccination administrative vs community coverage survey
Facility-based coverage Community-based coverage
Target (n) Coverage (%) 95% CI n Coverage (%) 95% CI p value
Zomba:
1 dose 1930 91.2 89.9–92.5 309 87.7 83.3–92.1 0.05
2 doses 1930 86.8 85.3–88.3 309 87.4 82.9–91.8 0.78
3 doses 1930 84.7 83.1–86.3 309 85.8 81.3–90.3 0.63
Rumphi
1 dose 4294 96.2 95.6–96.8 307 97.4 95.6–99.2 0.30
2 doses 4294 93.2 92.4–94.0 307 95.8 93.9–97.8 0.09
3 doses 4294 90.2 89.3–91.1 307 94.2a 91.7–96.7 0.03
Both districts
1 dose 6224 94.6a 94.0–95.2 616 92.6 89.9–95.3 0.03
2 doses 6224 91.2 90.5–91.5 616 91.6 89.0–94.2 0.77
3 doses 6224 88.5 87.7–89.3 616 90.0 87.2–92.7 0.29
CI confidence interval, % percentage, astatistically significant facility vs community based coverage
Table 4 Reasons (%) for no or partial vaccination cited by care
givers of un- or partially vaccinated eligible girls
Reason Rumphi
(n = 23)
Zomba urban
(n = 58)
Overall
(N = 81)
Girl not at risk for cervical
cancer
20.0 5.4 7.1
Does not believe vaccination is
good for child
0.0 13.5 11.9
Girl didn’t want to be
vaccinated
40.0 24.3 26.2
Vaccination venue was unclean
and unsafe
20.0 8.1 9.5
Location/time was inconvenient 0.0 21.6 19.1
Someone else said vaccine not
good idea
0.0 5.4 4.8
Others in community or school
were also refusing
0.0 2.7 2.4
Waiting time was unacceptable 0.0 5.4 4.8
Girls are too young for HPV
vaccine
0.0 5.4 4.8
Was not aware of HPV vaccine
program
20.0 5.4 7.1
Too much pain after 1st or 2nd
dose
0.0 2.7 2.4
Girl ill on vaccination day 0.0 8.1 7.1
Girl absent from school on
vaccination day
20.0 2.7 4.8
n number of respondents by district, N total number of respondents in
both districts
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Although the low coverage of out-of-school girls could
not be generalized to in-school girls; this finding raised
some fears that the health facility-based strategy in this
population may not produce intended effective (>80%)
coverage. Health facility- and child health day-based
strategies (other than the school strategy) in Cameroon
and Uganda also resulted in low coverage, ranging from
50% to 60% [18–20].
Conclusion
In Malawi, the implementation of a school-class-based
HPV vaccination strategy was feasible and resulted in a
high (>80%) coverage. However, the school- class-based
strategy may be associated with the vaccination of
under- and over-aged girls who are outside the vaccine
manufacturer’s stipulated age group of 9–13 years. The
health facility-based coverage for out-of-school girls re-
sulted in a low coverage, with only half of the target popu-
lation being fully vaccinated. Our findings highlight the
need to assess the immunogenicity associated with the ad-
ministration of a two- dose schedule to adolescent girls
aged younger or older than 9–13 years and effectiveness
of health facility-based strategies before rolling out.
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